[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transfusion-related-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transfusion-related-complication":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,80,116,144,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100492965","phase-1-individualized-or-conventional-transfusion-strategies-during-peripheral-va-ecmo-100492965",false,"NCT05699005","Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO","Comparison of an Individualized Transfusion Strategy to a Conventional Strategy in Patients Undergoing Peripheral Veno-arterial ECMO for Refractory Cardiogenic Shock: a Randomized Controlled Trial - ICONE","ICONE","Inclusion Criteria:\n\n* Age of 18 and older,\n* supported by peripheral VA-ECMO\n* for cardiogenic shock\n* Life expentency \\>90 days\n* Central venous line available ScVO2 measurement\n\nExclusion Criteria:\n\n* Pregnancy,\n* Lack of health insurance,\n* Opposition to blood transfusion,\n* Known congenital hemoglobin disease or disorder,\n* Metabolic alcaloosis with pH\\>7.8,\n* eCPR,\n* Legally incapacitated adults","ALL","18 Years",{"count":20,"type":21},236,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock.\n\nAn individualized transfusion strategy based on ScVO2 level, is compared to a conventionnal strategy based on predefined hemoglobin threshold. The primary endpoint is the consumption of packed red blod cells, secondary endpoints are subgroup analysis, mortality, morbidity, and cost-effectiveness",[27,28,29,30,31],"Cardiogenic Shock","Extracorporeal Membrane Oxygenation","Transfusion Related Complication","Anemia","Oxygen Delivery",[33,34,35,36,37,38],"ECMO","ECLS","Refractory cardiogenic shock","Transfusion","ScVO2","Outcome","RECRUITING","2026-06-30",{"date":42,"type":43},"2026-07-02","ACTUAL",{"date":45,"type":43},"2023-09-18",{"date":47,"type":21},"2028-12-18",{"name":49,"class":50},"University Hospital, Lille","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100362441","phase-1-s-nitrosylation-sno-therapy-during-autologous-blood-transfusion-100362441","NCT03999229","S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion","Phase 1 Study of S-Nitrosylation Therapy to Improve Tissue Oxygenation During Autologous Blood Transfusion in Healthy Volunteer","Eligibility Criteria\n\nRecruiting and studying of healthy human subjects with no pre-existing pathologic conditions from the local population. As a result the inclusion criteria is deliberately broad.\n\nInclusion Criteria\n\n1. Hemoglobin \\> 12 g\u002Fdl\n2. Healthy, non-pregnant adults with no pre-existing blood disorders or disease states that impact oxygen delivery.\n\n2a. Active blood and platelet donors will be sought as study participants since these individuals are familiar with the routines for blood withdrawal and re-infusion.\n\nExclusion Criteria\n\nThe exclusion criteria is derived from the American Red Cross(ARC) Standard Operating Procedure (SOP) for autologous donation AND the parameters set out in the investigational new drug application (IND).\n\n1. Individuals who are pregnant, breastfeeding, or are unwilling to avoid pregnancy during the study.\n2. Individuals with an anatomic anomaly that would increase the risks associated with placement of the vascular catheters.\n3. Individuals who report chronic diseases requiring medication of the heart, lungs, kidney, liver, etc or afflicted with any acute or chronic pathology that in the opinion of the screening physician makes them unsuitable for study.\n4. Individuals with a recent history of antibiotic therapy (check for underlying cause).\n5. Individuals unwilling to refrain from taking any phosphodiesterase 5 (PDE-5) inhibitor for at least 24 h prior to donation and\u002For autologous transfusion.\n6. Individuals taking a vitamin K antagonist (warfarin) or other anticoagulant (e.g. heparin, clopidogrel, enoxaparin or dalteparin).\n7. Individuals taking allopurinol, beta-adrenergic blockers, tricyclic antidepressants, meperidine (or related central nervous system (CNS) agents), or nitrates.\n8. Individuals on long-term antihistamine therapy 8a. The study physician will determine on a case by case basis the suitability for inclusion of individuals who control seasonal or acute allergies with occasional antihistamine use.\n9. Individuals with blood pressure parameters outside the normal range, i.e., higher than 130 mm Hg systolic and\u002For higher than 90 mm Hg diastolic; mild hypertension is acceptable by the Red Cross for blood donation.\n10. Individuals with heart rates outside the range of 50 to 100 beats per minutes or with a pathologic irregularity.\n\n10a. Pulses lower than 50 may be acceptable if the study participant participates in endurance training. The study physician will be consulted for evaluation.\n\n11\\. Individuals with an inherited or acquired blood coagulation disorder, congenital methemoglobinemia, or a familial hemoglobinopathy that impacts oxygen delivery (e.g. sickle cell).\n\n12\\. Individuals with any illness that may increase the risks associated with the study.\n\n13\\. Individuals who previously received blood products to treat an acute condition will be evaluated on a case by case basis.\n\n14\\. Individuals who report an acute or chronic disease state that may impact oxygen delivery.\n\n15\\. Individuals with evidence of diminished lung capacity.\n\n16\\. Individuals who might have difficulty with the placement of a face mask (e.g. claustrophobia, uncontrolled asthma, severe allergies, sensitive skin) and\u002For the inhalation of a product for approximately 2-3 hours.",true,"35 Years",{"count":62,"type":21},35,[24],"The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).",[29],[67,68,69,70],"S-Nitrosylation","Tissue Oxygenation","Anemia-induced tissue hypoxia","Red blood cell Transfusion","2025-11-25",{"date":73,"type":43},"2025-12-02",{"date":75,"type":43},"2019-07-25",{"date":77,"type":21},"2028-02-29",{"name":79,"class":50},"James Reynolds",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":101,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":51},"100547068","transfusion-surveillance-in-anaesthesia-100547068","NCT06403163","Transfusion Surveillance in Anaesthesia","Biological Transfusion Efficiency Registry Transfusion Surveillance in Anaesthesia","STAR","Inclusion Criteria:\n\n* all patients who have received an hemostasis product\n\nExclusion Criteria:\n\n* patient who refused to consent to data analysis and study participation",{"count":89,"type":21},50000,"2 Weeks","OBSERVATIONAL","the aim of this register is to collect exhaustively the different data available surrounding a transfusion act in the context of an active haemorrhage. The aim is to allow different modelling and analysis related to emergency transfusion.",[94,29,95,96,97,98,99,100],"Transfusion Reaction","Anesthesia","Anesthesia; Shock","Side Effect","Fresh Blood Stool","Blood Coagulation Disorder","Blood Loss",[102,103,104,105,106],"transfusion","monitoring","emergency situation","shock","fresh frozen plasma","2025-08-25",{"date":109,"type":43},"2025-09-02",{"date":111,"type":43},"2022-09-01",{"date":113,"type":21},"2030-12-31",{"name":115,"class":50},"Erasme University Hospital",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100501214","goal-directed-vs-empirical-tranexamic-acid-administrationin-cardiovascular-surgery-100501214","NCT05806346","Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular Surgery","Tranexamic Acid Administration Strategies in Cardiovascular Surgery: Goal-directed Tranexamic Acid Administration Based on Viscoelastic Test vs. Empirical Tranexamic Acid Administration","Inclusion Criteria:\n\n* patients who will undergo elective cardiovascular surgery employing cardiopulmonary bypass\n* patients who provide written informed consent\n\nExclusion Criteria:\n\n* pregnancy\n* refusal of allogenic blood transfusion\n* taking thrombin\n* history of thromboembolic and familial hypercoagulability disease\n* recent history of myocardial infarction or ischemic cerebral infarction (within 90 days)\n* hypersensitive to TXA\n* histroy of convulsion or epilepsy\n* taking hemodialysis\n* history of Heparin-induced thrombocytopenia","19 Years",{"count":125,"type":21},764,[127],"NA","The present study is a multi-center randomized prospective placebo-controlled non-inferiority trial.\n\nThe study's primary objective is to compare the amounts of postoperative bleeding using two different TXA administration strategies: empirical TXA administration vs. viscoelastic test-based goal-directed TXA administration in cardiovascular surgery.\n\nThe secondary objectives include comparing the incidents of hyper-fibrinolysis, thromboembolic complications, and postoperative seizures.\n\nResearchers assumed that goal-directed tranexamic acid (TXA) administration using viscoelastic field tests would not be inferior to the empirical TXA administration strategy in reducing postoperative bleeding and hyper-fibrinolysis. It also would be beneficial in lowering TXA-induced thromboembolic complications and seizures.",[130,131,29,132,133],"Heart Diseases","Vascular Diseases","Coagulation Disorder, Blood","Fibrinolysis; Hemorrhage","2024-12-15",{"date":136,"type":43},"2024-12-18",{"date":138,"type":43},"2023-08-01",{"date":140,"type":21},"2025-06-30",{"name":142,"class":50},"Konkuk University Medical Center",3,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":51},"100546790","individualized-anh-for-non-cardiac-surgery-100546790","NCT06399536","Individualized ANH for Non-cardiac Surgery","Individualized Acute Normovolemic Hemodilution for Non-cardiac Surgery With Anticipated High-dose Red Cells Transfusion","Inclusion Criteria:\n\n* Patients undergoing elective non-cardiac surgery with an anticipated red blood cells transfusion \\>8 units (or 1600ml)\n* Aged 18\\~75 years\n* Preoperative Hb level \\> 120g\u002FL for men and \\> 110g\u002FL for women.\n\nExclusion Criteria:\n\n* Refusal of blood transfusion\n* Cardiopulmonary insufficiency\n* Cerebrovascular disease\n* Renal impairment\n* Hemoglobinopathies or blood system diseases\n* Other situations not suitable for inclusion in clinical trial.","75 Years",{"count":153,"type":21},40,[127],"In this trial, we proposed an individualized acute normovolemic hemodilution (ANH), and conduct a randomized controlled trial to testify the effect of individualized ANH on red cells requirement for non-cardiac surgeries with anticipating major blood loss in adults.",[29,157],"Hemodilution",[159,160,161],"acute normovolemic hemodilution","individualized blood transfusion","clinical trial","2024-12-01",{"date":164,"type":43},"2024-12-04",{"date":166,"type":43},"2024-06-01",{"date":168,"type":21},"2026-12-31",{"name":170,"class":50},"West China Hospital",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":51},"100357444","impact-of-transfusional-practice-on-the-morbidity-and-mortality-of-patients-in-intensive-care-unit-100357444","NCT03934112","Impact of Transfusional Practice on the Morbidity and Mortality of Patients in Intensive Care Unit","Impact of Transfusional Practice on the Morbidity and Mortality of Patients in Intensive Care","PATMORE","Inclusion criteria:\n\n* Patient admitted to medical and surgical resuscitation units of Besançon and Dijon university hospitals, all causes considered\n* Patient admitted between 1st January 2012 to 31st December 2017",{"count":180,"type":21},150000,"This study will allow correlating transfusion monitoring and patients' prognostic according to the chosen outcome criteria.\n\nThese data could thus represent a basis for transfusion recommendations, except for intensive care and vital emergencies.\n\nIt will also bring information about the actual transfusion monitoring in intensive care unit (ICU), in the period following the stay in the ICU and after hospital discharge.",[29],"2024-09-05",{"date":185,"type":43},"2024-09-19",{"date":187,"type":43},"2020-01-03",{"date":189,"type":21},"2026-12",{"name":191,"class":50},"Centre Hospitalier Universitaire de Besancon"]